Fungal infection

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
5 Unique sponsors
7 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
J Anti-infectives (ATC J) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Azole antifungal 3 substances
Phase III: 2 Phase II: 1 Phase IV: 1 Phase I: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

2 trials
  • Basilea Pharmaceutica International AG Allschwil Commercial
    FOSMANOGEPIX
    2024-516216-16-00 8 countries 2026 n=94 Orphan
    Recruiting
  • F2G Limited Commercial
    AMPHOTERICINE B, LIPOSOME; OLOROFIM
    2024-513030-38-00 6 countries 2022 n=64 Orphan
    Ended

Phase II

1 trial
  • Elion Therapeutics Inc. Commercial
    N38-(1,3-DIHYDROXYPROPAN-2-YL)-2'-EPI-AMPHOTERICIN B-38-AMIDE; VORICONAZOLE
    2025-522835-32-00 4 countries 2026 n=54
    Recruiting

Phase IV

1 trial
  • Centre Hospitalier Universitaire Vaudois Academic
    FLUCONAZOLE; POSACONAZOLE
    2024-517211-79-00 2 countries n=153
    Pending

Phase I

1 trial
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    IMP not specified
    2025-524638-24-00 1 country n=10
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Elion Therapeutics Inc. Commercial 1 Phase II 1
Basilea Pharmaceutica International AG Allschwil Commercial 1 Phase III 1
F2G Limited Commercial 1 Phase III 0
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic 1 Phase I 0
Centre Hospitalier Universitaire Vaudois Academic 1 Phase IV 0
New trials by year
2022
1
2026
2
← All indication landscapes